Pooled trial data highlight lotilaner ophthalmic solution’s effectiveness for Demodex blepharitis
Lotilaner ophthalmic solution (0.25%) is a safe and effective treatment for Demodex blepharitis, significantly reducing collarettes, mite density, and erythema over 6 weeks with minimal adverse effects and high patient comfort, according to a pooled analysis of 2 pivotal clinical trials.
The Phase 2b/3 Saturn-1 and Phase 3 Saturn-2 trials assessed the treatments’s impact on reducing collarettes and mite density over 6 weeks.
The analysis included 833 participants, randomized to receive either lotilaner or a vehicle control. By day 43, 49.8% of those in the treatment group achieved near-complete collarette resolution compared to 9.9% in the control group (P < 0.0001). In addition, 85.1% of treated patients saw a reduction to ≤10 collarettes, while only 28.0% in the control group achieved the same outcome (P < 0.0001). Mite eradication and erythema cure rates were also significantly higher in the lotilaner group.
The treatment was well tolerated, with no serious ocular adverse events reported, and 92% of patients rated the drops as neutral to very comfortable. These findings reinforce lotilaner’s effectiveness as a safe and well-tolerated therapy for Demodex blepharitis.
Reference
Yeu E, Paauw JD, Vollmer P, et al. Safety and Efficacy of Lotilaner Ophthalmic Solution (0.25%) in Treating Demodex Blepharitis: Pooled Analysis of Two Pivotal Trials. Ophthalmol Ther. 2025;14(3):555-571. doi: 10.1007/s40123-024-01089-5. Epub 2025 Jan 28. PMID: 39873946; PMCID: PMC11825414.
Related Content
